Alan Craft - Academia.edu (original) (raw)
Uploads
Papers by Alan Craft
Epidemiology, Nov 1, 2009
Archives of Disease in Childhood, Feb 1, 1989
Archives of Disease in Childhood, Oct 1, 1999
British Journal of Cancer, Jul 22, 2014
Archives of Disease in Childhood, Jul 1, 1983
Pediatric Radiology, May 19, 2011
Archives of Disease in Childhood, Mar 1, 1974
Cancer Causes & Control, Apr 5, 2011
Journal of Epidemiology and Community Health, Aug 1, 2011
Journal of Epidemiology and Community Health, Sep 1, 2010
Medical and Pediatric Oncology, 1993
Ten patients (age range 3.2-26.3 yrs) with relapsed or resistant malignancies received a total of... more Ten patients (age range 3.2-26.3 yrs) with relapsed or resistant malignancies received a total of 20 courses of low dose continuous infusion doxorubicin (3 mg/m2/day for 28 days) delivered by portable Graseby infusion pumps via central venous catheters. Each patient received a median dose of 144 mg/m2 (range 87-261). Four patients responded to treatment (1 complete response (CR) and 3 partial response (PR)) and performance status improved in seven patients. Overall toxicity was minimal: WHO Grade 4 anaemia in 2/18 courses, Grade 4 neutropenia in 1/18, Grade 3-4 thrombocytopenia in 3/18, nausea and vomiting of Grades 2 and 4 in 4/20 and 1/20 respectively, and mucositis of Grades 2 and 4 in 2/20 courses each. Cardiac toxicity was assessed using echocardiography, and fractional shortening remained within normal limits in all patients. Low dose continuous infusion doxorubicin is a feasible, well tolerated, ambulatory therapy in children and may be an effective way of delivering doxorubicin with less toxicity, thus enabling the development of more dose intensive regimens.
British Journal of Cancer, Nov 20, 2014
Medical and Pediatric Oncology, 2001
Epidemiology, Nov 1, 2009
Archives of Disease in Childhood, Feb 1, 1989
Archives of Disease in Childhood, Oct 1, 1999
British Journal of Cancer, Jul 22, 2014
Archives of Disease in Childhood, Jul 1, 1983
Pediatric Radiology, May 19, 2011
Archives of Disease in Childhood, Mar 1, 1974
Cancer Causes & Control, Apr 5, 2011
Journal of Epidemiology and Community Health, Aug 1, 2011
Journal of Epidemiology and Community Health, Sep 1, 2010
Medical and Pediatric Oncology, 1993
Ten patients (age range 3.2-26.3 yrs) with relapsed or resistant malignancies received a total of... more Ten patients (age range 3.2-26.3 yrs) with relapsed or resistant malignancies received a total of 20 courses of low dose continuous infusion doxorubicin (3 mg/m2/day for 28 days) delivered by portable Graseby infusion pumps via central venous catheters. Each patient received a median dose of 144 mg/m2 (range 87-261). Four patients responded to treatment (1 complete response (CR) and 3 partial response (PR)) and performance status improved in seven patients. Overall toxicity was minimal: WHO Grade 4 anaemia in 2/18 courses, Grade 4 neutropenia in 1/18, Grade 3-4 thrombocytopenia in 3/18, nausea and vomiting of Grades 2 and 4 in 4/20 and 1/20 respectively, and mucositis of Grades 2 and 4 in 2/20 courses each. Cardiac toxicity was assessed using echocardiography, and fractional shortening remained within normal limits in all patients. Low dose continuous infusion doxorubicin is a feasible, well tolerated, ambulatory therapy in children and may be an effective way of delivering doxorubicin with less toxicity, thus enabling the development of more dose intensive regimens.
British Journal of Cancer, Nov 20, 2014
Medical and Pediatric Oncology, 2001